Skip to main content

Research Repository

Advanced Search

Outputs (29)

Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer (2018)
Journal Article
Joseph, C., Arshad, M., Kurozomi, S., Althobiti, M., Miligy, I. M., Al-Izzi, S., Toss, M. S., Goh, F. Q., Johnston, S. J., Martin, S. G., Ellis, I. O., Mongan, N. P., Green, A. R., & Rakha, E. A. (2019). Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer. Breast Cancer Research and Treatment, 174(2), 387-399. https://doi.org/10.1007/s10549-018-05085-9

Purpose
CD133/ prominin 1 is a cancer stem cell marker associated with cancer progression and patient outcome in a variety of solid tumours, but its role in invasive breast cancer (BC) remains obscure. The current study aims to assess the prognostic... Read More about Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer.

Connexin 43 is an independent predictor of patient outcome in breast cancer patients (2018)
Journal Article
Chasampalioti, M., Green, A. R., Ellis, I. O., Rakha, E. A., Jackson, A. M., Spendlove, I., & Ramage, J. M. (2019). Connexin 43 is an independent predictor of patient outcome in breast cancer patients. Breast Cancer Research and Treatment, 174(1), 93-102. https://doi.org/10.1007/s10549-018-5063-9

Purpose

Gap junctions are specialized membrane structures that form channels between adjacent cells allowing cell communication. Gap junctions and specifically Connexin 43 (Cx43) are down-regulated in cancer; however, there are contrasting reports... Read More about Connexin 43 is an independent predictor of patient outcome in breast cancer patients.

Glutamate dehydrogenase (GLUD1) expression in breast cancer (2018)
Journal Article
Craze, M. L., El-Ansari, R., Aleskandarany, M. A., Cheng, K. W., Al-Farsi, L., Masisi, B., Diez-Rodriguez, M., Nolan, C. C., Ellis, I. O., Rakha, E. A., & Green, A. R. (2019). Glutamate dehydrogenase (GLUD1) expression in breast cancer. Breast Cancer Research and Treatment, 174(1), 79–91. https://doi.org/10.1007/s10549-018-5060-z

Dysregulated cellular metabolism is regarded as one of the hallmarks of cancer with some tumours utilising the glutamine metabolism pathway for their sustained proliferation and survival. Glutamate dehydrogenase (GLUD1) is a key enzyme in glutaminoly... Read More about Glutamate dehydrogenase (GLUD1) expression in breast cancer.

Legumain is an independent predictor for invasive recurrence in breast ductal carcinoma in situ (2018)
Journal Article
Toss, M. S., Miligy, I. M., Gorringe, K. L., McCaffrey, L., Alkawaz, A., Abidi, A., Ellis, I. O., Green, A. R., & Rakha, E. A. (2019). Legumain is an independent predictor for invasive recurrence in breast ductal carcinoma in situ. Modern Pathology, 32, 639-649. https://doi.org/10.1038/s41379-018-0180-x

© 2018, United States & Canadian Academy of Pathology. Legumain is a proteolytic enzyme that plays a role in the regulation of cell proliferation in invasive breast cancer. Studies evaluating its role in ductal carcinoma in situ (DCIS) are lacking.... Read More about Legumain is an independent predictor for invasive recurrence in breast ductal carcinoma in situ.

Prolyl-4-hydroxylase Α subunit 2 (P4HA2) expression is a predictor of poor outcome in breast ductal carcinoma in situ (DCIS) (2018)
Journal Article
Toss, M. S., Miligy, I. M., Gorringe, K. L., Alkawaz, A., Khout, H., Ellis, I. O., Green, A. R., & Rakha, E. (2018). Prolyl-4-hydroxylase Α subunit 2 (P4HA2) expression is a predictor of poor outcome in breast ductal carcinoma in situ (DCIS). British Journal of Cancer, 119(12), 1518-1526. https://doi.org/10.1038/s41416-018-0337-x

© 2018, Cancer Research UK. Background: Extracellular matrix (ECM) plays a crucial role in tumour behaviour. Prolyl-4-hydroxlase-A2 (P4HA2) is a key enzyme in ECM remodelling. This study aims to evaluate the prognostic significance of P4HA2 in breast... Read More about Prolyl-4-hydroxylase Α subunit 2 (P4HA2) expression is a predictor of poor outcome in breast ductal carcinoma in situ (DCIS).

Co-expression of nuclear P38 and hormone receptors is prognostic of good long-term clinical outcome in primary breast cancer and is linked to upregulation of DNA repair (2018)
Journal Article
Johnston, S. J., Ahmad, D., Aleskandarany, M. A., Kurozumi, S., Nolan, C. C., Diez-Rodriguez, M., Green, A. R., & Rakha, E. A. (2018). Co-expression of nuclear P38 and hormone receptors is prognostic of good long-term clinical outcome in primary breast cancer and is linked to upregulation of DNA repair. BMC Cancer, 18, Article 1027. https://doi.org/10.1186/s12885-018-4924-2

Kinesin family member-18A (KIF18A) is a predictive biomarker of poor benefit from endocrine therapy in early ER+ breast cancer (2018)
Journal Article
Alfarsi, L. H., Elansari, R., Toss, M. S., Diez-Rodriguez, M., Nolan, C. C., Ellis, I. O., Rakha, E. A., & Green, A. R. (2018). Kinesin family member-18A (KIF18A) is a predictive biomarker of poor benefit from endocrine therapy in early ER+ breast cancer. Breast Cancer Research and Treatment, https://doi.org/10.1007/s10549-018-4978-5

PURPOSE: Identification of effective and reliable biomarkers that could be used to predict the efficacy of endocrine therapy is of crucial importance to the management of oestrogen receptor positive (ER+) breast cancer (BC). KIF18A, a key regulator o... Read More about Kinesin family member-18A (KIF18A) is a predictive biomarker of poor benefit from endocrine therapy in early ER+ breast cancer.

Targeting PARP1 in XRCC1-deficient sporadic invasive breast cancer or preinvasive ductal carcinoma in situ induces synthetic lethality and chemoprevention (2018)
Journal Article
Ali, R., Al-Kawaz, A., Toss, M. S., Green, A. R., Miligy, I. M., Mesquita, K. A., Seedhouse, C., Mirza, S., Band, V., Rakha, E. A., & Madhusudan, S. (2018). Targeting PARP1 in XRCC1-deficient sporadic invasive breast cancer or preinvasive ductal carcinoma in situ induces synthetic lethality and chemoprevention. Cancer Research, 78(24), 6818-6827. https://doi.org/10.1158/0008-5472.CAN-18-0633

© 2018 American Association for Cancer Research. Targeting PARP1 for synthetic lethality is a new strategy for breast cancers harboring germline mutations in BRCA. However, these mutations are rare, and reactivation of BRCA-mediated pathways may resu... Read More about Targeting PARP1 in XRCC1-deficient sporadic invasive breast cancer or preinvasive ductal carcinoma in situ induces synthetic lethality and chemoprevention.

The role of PIP5K1α/pAKT and targeted inhibition of growth of subtypes of breast cancer using PIP5K1α inhibitor (2018)
Journal Article
Sarwar, M., Syed Khaja, A. S., Aleskandarany, M., Karlsson, R., Althobiti, M., Ødum, N., Mongan, N. P., Dizeyi, N., Johnson, H., Green, A. R., Ellis, I. O., Rakha, E. A., & Persson, J. L. (2019). The role of PIP5K1α/pAKT and targeted inhibition of growth of subtypes of breast cancer using PIP5K1α inhibitor. Oncogene, 38(3), 375-389. https://doi.org/10.1038/s41388-018-0438-2

© 2018, The Author(s). Despite recent improvement in adjuvant therapies, triple-negative, and ER + subtypes of breast cancer (BC) with metastatic potentials remain the leading cause of BC-related deaths. We investigated the role of phosphatidylinosi... Read More about The role of PIP5K1α/pAKT and targeted inhibition of growth of subtypes of breast cancer using PIP5K1α inhibitor.

Clinicopathological and prognostic significance of Ras association and pleckstrin homology domains 1 (RAPH1) in breast cancer (2018)
Journal Article
Kurozumi, S., Joseph, C., Sonbul, S., Aleskandarany, M. A., Pigera, M., Alsaleem, M., Alsaeed, S., Kariri, Y., Nolan, C. C., Diez-Rodriguez, M., Johnston, S., Mongan, N. P., Fujii, T., Shirabe, K., Martin, S. G., Ellis, I. O., Green, A. R., & Rakha, E. A. (2018). Clinicopathological and prognostic significance of Ras association and pleckstrin homology domains 1 (RAPH1) in breast cancer. Breast Cancer Research and Treatment, 172(1), 61–68. https://doi.org/10.1007/s10549-018-4891-y

BACKGROUND: Ras association and pleckstrin homology domains 1 (RAPH1) is involved in cytoskeleton regulation and re-epithelialisation in invasive carcinoma and therefore may play a key role in carcinogenesis and metastasis. We herein investigated the... Read More about Clinicopathological and prognostic significance of Ras association and pleckstrin homology domains 1 (RAPH1) in breast cancer.